Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$36265 of $63500 - as of 2024-08-31
57%
Header Image
Fasoracetam for ADHD

Fasoracetam for ADHD

Fasoracetam (NFC-1, AEVI-001) is a racetam.
Fasoracetam is a non-stimulatory modulator (agonist) of all 3 groups of metabotropic glutamate receptors.
Fasoracetam is bioavailable when taken orally and is largely excreted unchanged in the urine.

In studies with rodents, it improved cognitive functions.
Fasoracetam was unsuccessful in Phase 3 trials for the treatment of vascular dementia. Studies in primates and rodents found no signs of dependence or addiction.1

Fasoracetam may be effective in the treatment of ADHD in people with certain mGluR mutations. This applies to around 10% of all ADHD cases. In all other cases, fasoracetam is probably ineffective.
A 5-week, open-label, single-blind, placebo-controlled and registered study in 30 adolescents aged 12-17 years with ADHD and mutations in mGluR network genes showed a significant improvement in ADHD symptoms without increased side effects.2
Two other registered studies found no improvement in ADHD symptoms in those with and without glutamate receptor gene mutations.3